Tags » GlaxoSmithKline

The 4 Best Brexit-Proof Foreign Stocks to Buy for 2017

After the U.K. voted in June to leave the EU, global stocks went into a tailspin—and almost immediately shrugged it off. Even blue-chip U.K. stocks traded at a premium (see chart below), as investors flocked to Britain-based multinationals, which got an added foreign-exchange boost thanks to the weakened pound. 395 more words


GSK kicks off final phase of testing anaemia drug

GlaxoSmithKline has started a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD). 291 more words


GSK study of Nucala for rare EGPA disease goes well, one non-related death

GlaxoSmithKline has announced today that both all endpoints were met in a pivotal phase III study of mepolizumab for rare disease Eosinophilic Granulomatosis with Polyangiitis (EGPA), approved as Nucala as an add-on treatment for some types of asthma in adult patients, and teenage patients in the U.S. 299 more words


GSK files for chronic lung disease drug to FDA

GlaxoSmithKline has submitted with the US Food and Drug Administration (FDA) for its drug against lung disease – chronic obstructive pulmonary disease (COPD).

The announcement by GlaxoSmithKline and Innovivatoday, of the filing for the once-daily, closed triple combination therapy fluticasone furoate/ umeclidinium/ vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD), follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018. 289 more words


GlaxoSmithKline tops access to medicine list for fifth time

#GlaxoSmithKline  GlaxoSmithKline tops access to medicine list for fifth time  British firm GlaxoSmithKline has come top of the Access to Medicine index, which ranks the 20 leading pharmaceutical companies operating in developing countries every two years. 40 more words

GSK's CEO Explains How Big Pharma Can Help the Poor and Still Make Money

Big pharma has been a persistent villain in the public’s consciousness over the past year in the wake of exorbitant drug price hikes, including on ancient medications. 333 more words


Here's What We Could Be Doing to Stop Pandemics Like Zika and Ebola

A boiling pot of global conditions, like ubiquitous travel and the growing populations of developing cities, have led to an outbreak of pandemics like Ebola, Zika, SARs, and even the flu over the past decade. 389 more words